Advantage of CERo’s CER receptor lies in native human protein-based antigen binding: CEO
CERo Therapeutics Holdings, Inc. is a biotechnology company pioneering engineered T cell immunotherapies to combat cancer, with a focus on hematologic malignancies and solid tumors.…